Based on Anika Therapeutics Inc’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $27.18 million and quarterly net profit of $6.89 million. In comparison, last year the company earned revenue of $25.79 million and had a net profit of $8.95 million. The company has a one-year high of $60.29 and a one-year low of $41.64. ANIK’s market cap is $808.2M and the company has a P/E ratio of 25.88.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anika Therapeutics, Inc. is global medical technology company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration and wound healing. The company’s products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body.